A Rare Breakthrough in a Disease That Offers Little Time
For patients diagnosed with bile duct cancer, the prognosis has long been bleak. Cholangiocarcinoma is typically caught late, when surgery is no longer viable, and fewer than one in three people in England survive beyond a year of diagnosis. Treatment options have, until now, been critically limited. That picture shifted this week when the National Institute for Health and Care Excellence gave its approval for zanidatamab — a targeted antibody therapy that, according to clinical trial data, could alter the trajectory of the disease in ways previously thought unlikely.
When the Biology of a Tumour Becomes the Target
The drug, marketed under the name Ziihera and developed by Jazz Pharmaceuticals, works by identifying and blocking a protein known as HER2 — a molecule that, when overexpressed, accelerates tumour growth. Rather than deploying the broad-spectrum assault of chemotherapy, zanidatamab works with the body’s own immune system, directing it to seek out and destroy cancer cells while simultaneously suppressing HER2 activity to prevent further proliferation. It is the first HER2-targeted therapy that NICE has recommended for biliary tract cancer in England — a distinction that underscores both the novelty of the approach and the historic absence of effective alternatives.
Survival Figures That Demand Attention
The clinical evidence behind the approval is striking. Patients receiving zanidatamab survived an average of 18.1 months — nearly triple the 6.2 months recorded among those on existing second-line treatments. In a cancer where time is measured in weeks rather than years, that difference is not incremental; it is, for many patients, the difference between seeing another winter or not. The treatment is administered intravenously every two weeks, and NICE estimates that around 65 patients per year in England will be eligible.
Helen Knight, director of medicines evaluation at NICE, welcomed the decision, noting that patients and clinical experts consulted during the appraisal process had been clear about the potential impact. “This treatment would make a huge difference by extending people’s lives and improving their quality of life,” she said — “something that was not always possible with chemotherapy.”
The Weight of Expectation from the Patient Community
For charities working in this space, the approval carries particular resonance. Helen Morement, chief executive of AMMF — the UK’s dedicated cholangiocarcinoma charity — said the organisation had heard directly from patients and families during the NICE appraisal about what zanidatamab had meant to them. “We are therefore pleased,” she said, “that more people with advanced HER2-positive disease will be able to access this life-extending treatment through the NHS.”
That access has been made possible partly through a commercial agreement between NICE and Jazz Pharmaceuticals, under which the manufacturer has agreed to supply the drug to the NHS at a discounted rate. The terms of that discount have not been disclosed publicly, as is standard practice in such arrangements.
What This Means for NHS Cancer Care
The approval represents a meaningful, if targeted, step forward in the NHS’s capacity to treat rare and difficult-to-manage cancers. Cholangiocarcinoma remains a relatively uncommon diagnosis, and the cohort of patients who carry the HER2-positive variant eligible for this treatment is small. Yet the significance of the decision extends beyond the numbers. It signals a broader shift in oncological thinking — away from generalised chemotherapy regimens and towards precision medicine that targets the specific molecular characteristics of a tumour. For a disease in which progress has been frustratingly slow, that shift may offer the clearest indication yet that more effective options are within reach.
